Meeting
2015 ASCO Annual Meeting
Survival impact of switching to different topoisomerase I or II inhibitors-based regimens (topo-I or topo-II) in extensive-disease small cell lung cancer (ED-SCLC): supplemental analysis from JCOG0509.
Authors
Shogo Nomura
Center for Research Administration and Support, National Cancer Center, Kashiwa, Japan
Shogo Nomura , Shigeki Umemura , Kiyotaka Yoh , Tomohiro Shinozaki , Taro Shibata , Kenichi Nakamura , Miyako Satouchi , Yuichiro Ohe , Haruhiko Fukuda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
000000720
Citation
J Clin Oncol 33, 2015 (suppl; abstr 7571)
DOI
10.1200/jco.2015.33.15_suppl.7571
Abstract #
7571
Poster Bd #
319
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A descriptive study on the treatment and outcomes of patients with platinum-sensitive, advanced, BRCA- or PALB2-related pancreatic cancer who have progressed on rucaparib.
First Author: Timothy J Brown
Poster
2016 ASCO Annual Meeting
TRIBE-2 by GONO group: A phase III strategy study in the first- and second-line treatment of unresectable metastatic colorectal cancer (mCRC) patients.
First Author: Chiara Cremolini
Poster
2015 Gastrointestinal Cancers Symposium
Novel chemotherapy combinations for metastatic gastric adenocarcinoma (mAGC): An updated meta-analysis.
First Author: Anna Dorothea Wagner
Poster
2014 ASCO Annual Meeting
Randomized phase 2 study of carboplatin plus irinotecan (CI) versus carboplatin plus amrubicin (CA) for extensive disease small-cell lung cancer (ED-SCLC): NJLCG0901.
First Author: Yosuke Kawashima